INTRODUCTION

Valsartan (VAL,
) is an antihypertensive drug belonging to the angiotensin II receptor antagonists class called sartans, 1 which is marketed in an amorphous form. Such solids differ from crystalline materials in lacking long-range order, although some short-range order may be present. 2, 3 Amorphous active pharmaceutical ingredients (APIs) have been used in the development of pharmaceutical solid formulations due to factors such as increased solubility and dissolution rate compared to crystalline forms. [4] [5] [6] However, amorphous APIs are usually less stable than their crystalline counterparts. The occurrence of polymorphism in crystalline pharmaceuticals and its impact on physicochemical properties is well documented, [7] [8] [9] [10] but it is also known that amorphous materials can have different physicochemical properties, depending on previous thermal history, time of storage and preparation method. 11-15 Amorphous materials can exist in different kinetic states, and the term pseudopolyamorphism or relaxation polyamorphism has been used to describe this phenomenon. 2 Polyamorphism, the possible existence of two or more distinct amorphous forms of the same compound separated by a clear phase transition has been reported for inorganic compounds [16] [17] [18] and discussed in the context of pharmaceuticals, 2, 10, 12, 19 although, to our knowledge, there is no definitive example of polyamorphism in pharmaceutics. nitrogens numbered. Numbering scheme used as in Refs. 20, 21 The dihedral angle C-6-N-1-C-5-O-1, τ, that determines the amide cis (τ ≈180°) vs trans (τ ≈ 0°) conformation, as defined in Ref. 21 , is shown. (B) The structure of the independent molecule of valsartan in the asymmetric unit and hydrogen bonding adapted from Ref. 20 The τ torsion angle is ~171°, corresponding to the cis isomer. Hydrogens are omitted for clarity.
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Despite a wide variety of analytical techniques available, the structural characterization of subtle differences between different amorphous forms of active pharmaceutical ingredients remains challenging.
It is also important to understand the nature of molecular mobility in amorphous APIs, because molecular relaxation may take place during storage. Solid-state NMR (SSNMR) has been widely used to study molecular dynamics in pharmaceutics. [22] [23] [24] [25] For example, Luthra et al. studied changes in molecular dynamics of model drug systems during annealing by Differential Scanning Calorimetry (DSC) 26 and 13 C NMR relaxation times. 27 They observed that in most cases annealing leads to longer T 1 and T 1ρ NMR relaxation times, indicating a slowing of the local dynamics. Abdul-Fattah et al. observed that higher temperature annealing decreased molecular mobility as measured by isothermal calorimetry and improved chemical stability. 28 Various analytical methods have been used to characterize the solid state of valsartan. Tran et al. studied the influence of various types of solvents on the re-crystallisation behaviour of two sources of valsartan by DSC, powder X-ray diffractrometry (PXRD) and scanning electron microscopy, 29 and found significant differences in morphology, structure and dissolution rate among the recrystallized samples.
The lack of strong Bragg diffraction peaks in the PXRD results suggest, however, that most of the forms produced were essentially amorphous with different levels of local order rather than crystalline. The commercially available form (termed here the as-received, or AR, form) and the amorphous form obtained by quench-cooling (here called the AM form) were characterized by us using thermal methods and PXRD. 30 The studies revealed significantly different glass transition temperatures for both materials and a higher degree of structural ordering in the marketed form. The crystal structure of a highly crystalline form of valsartan and its ethanol solvate have been recently published, 20 characterized by various solid-state techniques and compared to the marketed amorphous form.
Solid-state NMR is a powerful technique for the characterization of solid pharmaceuticals. 22, 31, 32 SSNMR has the advantage of providing localised chemical information on the crystalline or amorphous state, unlike bulk methods such as DSC or PXRD. SSNMR was successfully employed to characterize different polymorphic and amorphous forms of other sartans (candesartan, irbesartan and losartan).
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Bauer et al. reported that the closely related system irbesartan exists in two different crystal structures due to tautomerism in the tetrazole ring. 33 The focus of this study was to characterize two different amorphous forms of valsartan to provide insight into their amorphous structures and molecular mobility, employing solid-state NMR as a primary investigation tool supported by solution-state NMR, FT-IR, and TMDSC. Dissolution tests were also carried out to compare dissolution rates of the two forms.
EXPERIMENTAL SECTION Materials
Valsartan (form AR, as-received, pharmaceutical grade) was obtained from Polpharma, Starogard
Gdański, Poland and used without further treatment. The non-crystalline nature of the material was confirmed by PXRD (see Figure S1 of the Supporting Information) and the lack of birefringence when analyzed by polarizing light microscopy. We have also analyzed materials from two other suppliers (Zydus Cadila, Ahmedabad, India and Wuhan Fortuna Chemical Co. Wuhan, China) and all samples were essentially identical by DSC and TMDSC as the sample (AR) used here. Its fully amorphous form (form AM) was prepared immediately prior to experimental measurements in DSC pan in the instrument, in the NMR rotor in the probe or in an oven, by heating sample to 130-140 °C, holding for 10-20 min then cooling with at least approximately 3 °C min -1 cooling rate to room temperature. The purity of both AR and AM materials was verified by solution 1 H and 13 C NMR.
Attempts to obtain crystalline material by re-crystallization based on previous published reports or patents 20, [36] [37] [38] [39] were unsuccessful.
Intrinsic and apparent dissolution testing
The Intrinsic Dissolution Rate (IDR) of both amorphous samples was measured by the rotating disc method 40 using the Wood apparatus in an Erweka DT60 dissolution testing station (ERWEKA GmbH, Germany). 150 mg of API was compressed at 1300 psi and held for 40 s in a die to form an 8 mm 7 diameter disc. Dissolution studies were performed in 900 mL of deionisedand deaerated water (pH = 6.9, conductivity < 0.1 µS cm -1 ) maintained at a temperature of 37 ±0.5 °C and disk rotation speed of 100 rpm. Dissolution studies were carried out for 120 minutes and the concentration of API was determined on-line every 1 minute by a UV spectrophotometer at 250 nm (120 points). All measurements were performed in triplicates. IDR, the rate of mass transfer from solid to liquid state when conditions such as surface area, pH, ionic strength and stirring speed are kept constant, was determined using the following equation 41 :
where C is the drug concentration at time t, V is the volume of the test solution, S is the surface area of the disc, k is intrinsic dissolution rate constant, and C s is the saturation solubility of the drug. The IDR was calculated from slope of each curve for a time period of 0-120 min.
The apparent dissolution of both amorphous samples was measured by an on-line closed loop semi-automated flow through a cell dissolution system (SOTAX AG, Switzerland) using the Apparent Dissolution method defined in Chapter 2.9.43 of the Ph. Eur. 8.0. 42 The dissolution system consisted of: SOTAX CE 7 unit, SOTAX CP 7-35 piston pump, reservoirs for the dissolution medium (SIMAX 1 L orange glass bottles placed on magnetic stirrers with integrated temperature control plate) and doublebeam UV-Vis spectrophotometer Nicolet Evolution 300 (Thermo Electron Corporation, USA). Each 12 mm diameter cell was prepared by placing a 5-mm ruby bead in the apex of the cone to protect the inlet tube, and glass beads were added to the cone area to form a bead bed. Two sieves separated by a glass microfiber filter (GF/D Whatman with a retention capacity of 2.7 μm) and 50 mg of powder to be studied were respectively placed on the top of the layer of beads. The cell was closed with the prepared insert and the filter head consisting of one sieve and a glass microfiber filter (GF/F Whatman with a retention capacity of 0.7 μm). The closed-loop configuration used a 1000 mL of deaerated ultra-pure water (pH = 6.9, conductivity < 0.1 µS cm 
(where F is the fraction of drug dissolved at time t and k D is the dissolution rate constant 43 ) was fitted to the three individual dissolution profiles with linear least-squares curve-fitting technique using DDSolver software. were too long to measure with any precision.
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NMR measurements
Proton MAS spectra were recorded using a Varian InfinityPlus 500 spectrometer operating at a 1 H frequency of 499.70 MHz. A Bruker MAS probe using 1.3 mm diameter zirconia rotor was employed.
Spectra were typically acquired using a recycle delay of 10 s, 64 transients and spin rate of 67 kHz.
Spectra were also recorded at 43 and 53 kHz spinning rate, where frictional heating is significantly lower, NMR data were processed using gsim 48 51 for the crystalline valsartan given in Ref. 20 All calculations were performed using the PBE functional 52 using on-the-fly generated ultrasoft pseudopotentials. Geometry optimisations for all atoms were carried out with the centre of mass fixed and a cut-off energy of 600 eV, with integrals taken over the Brillouin zone using a Monkhorst-Pack grid 53 with 12 k-points and the unit cell parameters 11 fixed to the values determined by single crystal XRD. NMR calculations used the same cut-off energy and Brillouin zone integration.
FT-IR measurements
Fourier transform infra-red spectroscopy was carried out using an Alpha Bruker FT-IR spectrometer in KBr pellets. Spectra were recorded at room temperature from 4000 to 500 cm -1 collecting 64 scans with a resolution of 2 cm -1 .
TMDSC measurements
Temperature-modulated DSC (TMDSC) curves were obtained using a DSC Q1000 TA Instrument Inc.
(V9.9 Build 303) with an underlying heating rate of 3 °C min -1 and a temperature modulation with amplitude of 1.5 °C and period of 60 s (this is sometimes termed "standard TMDSC") from 25 to 120 °C under a nitrogen gas flow of 50 mL min -1 . The samples were then cooled at 25 °C min -1 to 20 °C without modulation and reheated to 120 °C with modulation in a second run.
The enthalpy change after isothermal physical ageing was determined as a function of ageing time. Samples were first heated to 120 °C and held for several minutes to eliminate the effect of prior thermal history and then cooled at 25 °C min -1 below the glass transition temperature to the ageing temperature, T a , which was 30, 40, 50 or 60 °C. The samples were maintained at T a for specified times ranging from 0 to 16 hrs, and then cooled at 25 °C min -1 to 25 °C. A subsequent heating scan at 3 °C min -1 by TMDSC to 120 °C provides the data for the aged samples. 54, 55 The modulation parameters were the same as above.
The equipment was calibrated with indium (m. p. = 156.65 °C, ΔH f = 28.45 J g -1 ), and at least two tests were run on each sample. Relaxation events are quoted as an onset temperature. Glass transition temperatures are quoted as midpoints. All values were determined using TA Universal Analysis 2000 V4.5A software. Errors are quoted as one standard deviation.
RESULTS AND DISCUSSION
Intrinsic dissolution rate (IDR) and apparent dissolution rate (ADR)
The dissolution profile of an API can have a profound impact on both pharmacokinetic and pharmacodynamic parameters. 56 generally associated with increased solubility and dissolution rates. [4] [5] [6] It is, therefore, surprising to find that the fully amorphous material (AM form) has the lower dissolution rate. Figure 3 shows 13 C CP MAS NMR spectra of the two valsartan forms. Both spectra are relatively broad, reflecting the amorphous nature of the materials as reported elsewhere (see Figure S1 of Supporting Information). 30 The resonances were assigned based on 13 C solution-state NMR and by computational prediction of chemical shifts based on the crystal structure of Ref.
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Carbon-13 SSNMR
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, although assignment is limited by peak overlap and the broadness of the resonances. The main difference between AR and AM spectra is for carbons directly bonded to the amide nitrogen (N-1) i.e. C-11 and C-6. In the fully amorphous material, the C-11 signal is broadened and at higher chemical shift (Δδ C = +2.1 ppm). The C-6 resonance at 65.8 ppm in the AR spectrum is split into two broad signals with maxima at 62.3 and 67.3 ppm in the AM form spectrum (clearer in the insets acquired at 6 kHz MAS rate in Figure 3C ). are noticeably sharper at 110 °C, which corresponds to increased molecular mobility. In contrast there is little narrowing of the aromatic region, implying that the mobility of the alkyl regions is local rather than affecting the molecules as a whole. Equalisation of the cis vs trans distribution has occurred for the AR form during its glass transition. Similar behaviour for an API, captopril, containing amide bond but in an initially crystalline form, was observed during melting of an initially crystalline material by Wang et. al.
using VT FT-IR microscopy. 58 Similarly amide cis-trans interconversion in the solid state was postulated as the origin of polymorphism in fosinopril sodium using SSNMR and FT-IR. 
Nitrogen-15 SSNMR
Solid-state 15 N CP MAS NMR has been successfully employed to examine polymorphism of a closely related system, irbesartan. 33 Like irbesartan, valsartan can potentially exist in two tautomeric forms of the tetrazole ring i.e. as 1,2,3,4-tetrazole or 1,2,3,5-tetrazole as presented in Figure 5A . f Values originally reported with respect to nitrate resonance of solid external ammonium nitrate but here reported relative to nitromethane for consistency.
Fourier transform infra-red spectroscopy (FT-IR)
FT-IR measurements revealed only subtle differences between the two forms, cf. Figure S7 of the Supporting Information. AR valsartan shows absorption bands at 1732.1 cm -1 and 1603.8 cm -1 , assigned to carboxyl carbonyl (C-10) and amide carbonyl (C-5) stretching vibrations respectively, that are potentially sensitive to changes in hydrogen bonds. There was, however, no change in the AM form in the carboxyl carbonyl band (1732.1 cm -1 ), while the C-5 carbonyl peak shifted towards higher wavenumber (1605.8 cm -1 ). This is consistent with the differences in the forms relating to cis-trans conformational changes, although changes in the intermolecular hydrogen bonds between C(5)O and the tetrazole N(5)H group could also be a factor. As well as minor changes in the fingerprint region (inset of Figure S7 ), there is some attenuation of the broad peak centred about 3436 cm -1 (N(5)H and/or OH) which is likely to reflect changes in hydrogen bonding.
Molecular mobility from NMR relaxation times
Variable-temperature, wideline (static) 1 H spin-lattice relaxation time, T 1 H , experiments provide information on molecular mobility of both forms. T 1 H is sensitive to motional processes of the order of the 1 H NMR frequency, 25 here 300 MHz, and is typically sensitive to high-frequency local motions. The Wideline measurements of T 1 H provide an overview of high-frequency local motions which can be refined by measurements of 13 C T 1 relaxation times (at the expense of greatly increased experimental time), since these provide information on site-specific dynamics. The detailed values are given in Table   SI of the Supporting Information and the results for characteristic carbons are shown in Figure 7 . The relaxation behaviour of the aliphatic carbons of the butyl chain (C-1-C-3) and the isobutyl group, Figure   7A -C, is very similar and essentially identical between forms. The temperature dependence of the dynamics driving the relaxation can be fitted by plotting the relaxation times as a function of the inverse of the temperature. This dependence can be interpreted, in terms of empirical activation barriers of the order of 8-12 kJ mol -1 ( Figure S8 , Supporting Information). Note how the major changes in bulk molecular mobility associated with the glass transition are not apparent from these relaxation times. In contrast, the aromatic carbons have relatively long relaxation times at ambient temperature which drop significantly at the glass transition, Figure 7E . This change is smooth for the truly amorphous material, but there is some evidence of a more step-like behaviour for the AR material. This suggests that the glass transition is associated with an "unlocking" of the aromatic rings. The relaxation time of C-4, Figure 7D , behaves somewhat differently to that of the other aliphatic carbons, which is consistent with amide group having different motional character to the alkyl chain and isobutyl group. the AR material below the glass transition are higher than for totally amorphous valsartan, but converge above T g . These differences are much smaller than those typically observed between amorphous and truly crystalline materials. 24 Experiments to measure site-specific 1 H T 1ρ values by transferring the partially relaxed 1 H magnetisation to 13 C via cross-polarisation prior to measurement were relatively uninformative, showing uniform behaviour across sites, cf. Figure S9 and Table SII of Supporting Information, although again a more step-like character to the temperature dependence was observed for the AR material. Spin-diffusion between 1 H will tend to equalise T 1ρ H values, which may, in any case, be probing overall bulk mobility rather than site-specific motions.
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The effect of annealing on the AM form During physical ageing amorphous materials lose excess enthalpy as they evolve towards more stable arrangements. This enthalpy loss is recovered by the system during the heating DSC step and is measured as an integral of enthalpy recovery peak, which overlaps with a change of heat capacity at glass transition on standard DSC. Such enthalpy relaxation reflects the molecular mobility in the glassy state. 62 The impact of annealing at different temperatures below the glass transition was investigated by temperature- Lines drawn between points are guides for the eye.
As summarised in Table III tend towards those of the AR material with increased annealing time. This is consistent with the mobility behaviour of the amorphous material evolving towards that of the AR material as a result of annealing.
T 1 C relaxation times were measured for the annealed material, but the poorer signal-to-noise ratio in these experiments meant that any variations were too small to be observed. Similarly, changes in the 13 C spectrum on annealing were too small to be observed. Note that no significant changes were observed by TMDSC after ageing of the AR sample at 60 °C for up to 16 hours. NMR. The signals from protons bonded to C-6 and C-11 are broadened in the AM material due to amorphisation and changes in the cis-trans distribution, while changes in the high-frequency signals are consistent with significant differences in the hydrogen bonding involving the tetrazole and acid hydrogens. Nitrogen-15 NMR experiments confirmed that both forms exist as the 1,2,3,4-tetrazole tautomer. NMR relaxation times show subtle differences in local and bulk molecular mobility between both forms, which can be connected with the glass transition, the stability of the glassy material and its response to ageing.
Both intrinsic and apparent dissolution profiles show significant differences in dissolution kinetics for examined amorphous solid-states of valsartan. As amorphous materials have higher free energy, they usually have a greater solubility and dissolution rate than corresponding crystalline forms.
Surprisingly, the less ordered, fully amorphous material (AM) has significantly lower dissolution rate than the apparently more ordered AR material. The results demonstrate that the method of preparation of amorphous valsartan can have a significant impact on its dissolution behaviour. These differences in dissolution rate are probably associated with the differences in hydrogen-bonding arrangements observed 
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Solid-state NMR, in conjunction with complementary methods, such as TMDSC, allows the molecular origins of the disorder in these materials to be probed. This in turn facilitates the design of future APIs, either to deliberately stabilise amorphous materials, or to avoid the risks of poorly crystalline forms.
ACKNOWLEDGMENTS
The authors would like to thank Ms Kinga Hyla (Poznań University of Medical Sciences) for her assistance with dissolution studies and Dr Martin Dračínský (Academy of Sciences, Prague) for help with CASTEP calculations. Also, the authors acknowledge Polpharma SA Company (Starogard Gdański, Poland) for supplying valsartan used in this study.
SUPPORTING INFORMATION
Supporting Information mentioned in the main text: X-ray diffractograms of AR and AM forms of valsartan; plots of 13 
